News and Trends 20 Nov 2017 After Failed Trial, French Biotech Gets Good News for its Peanut Allergy Therapy DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy in children, though its efficacy is uncertain. DBV Technologies saw its stock go down by 45% last month after releasing Phase III data for ViaSkin Peanut, a treatment delivered via a skin patch aimed at reducing peanut allergy in children aged […] November 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 Update: The First Drug for This Rare Kidney Disease May Come From a French Biotech Update (6/11/2017): ADV7103 has maintained its efficacy in a 6-month extension of the Phase III study. In 79% of the patients, the blood bicarbonate levels were kept within the normal range after 6 months of treatment, further supporting its push to become the first treatment for the disease on the market. Originally published 11/9/2017 Advicenne has […] November 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Oct 2017 French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexus, based in Lyon, starts trading on Euronext Paris today. The company starts off with a market cap of €47.5M after closing a €19.6M IPO. With the money raised, the company […] October 30, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Oct 2017 French Biotech Gets Together with L’Oréal to Clean up our Streets Carbios and L’Oréal have had enough of the plastics bags and packaging littering our streets and will form a consortium for the bio-recycling of plastic on an industrial scale. Today, you’ll struggle to walk along a street without seeing plastic bottles, bags, and wrappers dropped by the wayside… but thankfully, help is at hand. Carbios, […] October 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market Montpellier-based Deinove has developed a bacterial anti-aging skincare product, which has shown its safety and healing capacity in studies so far. Deinove specializes in high-value compounds from rare bacteria, in particular, the Deinococcus genus. It has announced that it will launch its first cosmetic product into the anti-aging skincare market in 2018, which is based on a […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 24 Oct 2017 Where to Find the Money to Get Your Biotech Startup Up with the Big Boys What do you need to kickstart your own biotech company? A great idea, of course. Industry knowledge, a plus. Money… This could be tricky. Breaking into the biotech industry is one of the most expensive decisions that you can make. First, you need ground-breaking science that has what it takes to change its respective field, […] October 24, 2017 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 Transgene‘s Hepatitis B Vaccine Does the Business at Phase I The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has […] October 23, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of a Phase III trial that was key to the approval of a treatment to reduce peanut allergy in children. After 12 months, 35% of children […] October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 Biotech Crosses the Channel to Raise €9.7M for its Diagnostics Tools Novacyt will use the money raised on the AIM market, London, to expand its manufacturing capacity and continue research looking into new techniques. Novacyt specializes in diagnostic tools for a number of indications, including cancer and infectious diseases. Today, it has announced that it has raised €9.7M by placing stocks on the London-based Alternative Investment Market (AIM). […] October 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2017 Genfit Gets €180M Cash Injection to Bring its Pipeline to Market Elafibranor, Genfit’s lead candidate, will continue its march towards the market with the added boost of massive financial support. Genfit is a leader in the development of diagnostic tools and therapeutics for metabolic and inflammatory diseases. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH) – an inflammatory disease of the liver. The company has raised €180M by selling bonds […] October 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 17 Oct 2017 World’s First Molecular Computer Makes Data Storage 100 Times Smaller A team of French scientists has built the first molecular computer using polymers to store data, making each bit 100 times smaller than with current data storage. Just eight bytes encoding the word “Sequence” in ASCII code. A feat for the team of researchers that encoded and read the word using a synthetic polymer sequence. Their […] October 17, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Biotech Power-Couple Sees Positive Phase II Results For Inflammatory Disease Drug Regeneron and Sanofi’s drug, dupilumab, has met primary and secondary endpoints for the treatment of eosinophilic esophagitis. The biotech-biopharma giants have announced that their candidate, Dupilumab, demonstrated good efficacy during a Phase II trial. The drug is designed for use against eosinophilic esophagitis, a nasty inflammatory disease of the esophagus that makes it difficult to swallow. […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email